Brief: Kinnate Biopharma Receives Fast Track Designation From FDA For Cancer Therapy
14/02/2023 21:49
Feb 14 (Reuters) - Kinnate Biopharma Inc KNTE.O :
* KINNATE BIOPHARMA INC. RECEIVES FAST TRACK DESIGNATION
FROM THE
U.S. FOOD AND DRUG ADMINISTRATION FOR KIN-3248, AN
INVESTIGATIONAL PAN-FGFR INHIBITOR
Source text for Eikon: ID:nGNX2wmz4q
Further company coverage: KNTE.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kinnate Biopharma
See all newsKinnate Biopharma Inc reports results for the quarter ended in December - Earnings Summary
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Brief: XOMA Announces Calculation Of Additional Price Per Share And Extension Of Expiration Date For Tender Offer For Kinnate Biopharma Inc
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview
Kinnate Biopharma Inc expected to post a loss of 44 cents a share - Earnings Preview